Mumbai: Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug-Indacaterol + Mometasone for patients suffering from uncontrolled asthma in India.
Novartis Europharm Generic Bemrist Breezhaler (Indacaterol;Mometasone)Receives Approval in Europe
Novartis Europharm Generic Atectura Breezhaler (Indacaterol;Mometasone) Receives Approval in Europe
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended eight new medicines for approval, including Novartis’ respiratory triple therapy Enerzair Breezhaler.
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Enerzair breezhaler, a new asthma treatment which includes an optional digital sensor.
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its March 2020 meeting. In line with EMA’s measures to limit the spread of COVID-19, the meeting was held virtually.
Having made its marketing pitch to the EU regulator, Novartis on Thursday unveiled positive pivotal study data supporting the use of its inhaled asthma treatment.